GlycoVaxyn
Company developing a broad portfolio of bioconjugate vaccines to prevent common bacterial infections using its proprietary glycoprotein technology.
Launch date
Employees
Market cap
-
Enterprise valuation
€173m (Public information from Feb 2015)
Company register number CH-020.3.028.196-4
Zurich Canton of Zürich (HQ)
Authorizing premium user...